Consideration of a new definition of clinically relevant myocardial infarction after coronary revascularization

An expert consensus document from the society for cardiovascular angiography and interventions (SCAI)

Issam D. Moussa, Lloyd W. Klein, Binita Shah, Roxana Mehran, Michael J. Mack, Emmanouil S. Brilakis, John P. Reilly, Gilbert Zoghbi, Elizabeth Holper, Gregg W. Stone

Research output: Contribution to journalArticle

232 Citations (Scopus)

Abstract

Numerous definitions have been proposed for the diagnosis of myocardial infarction (MI) after coronary revascularization. The universal definition for MI designates post procedural biomarker thresholds for defining percutaneous coronary intervention (PCI)-related MI (type 4a) and coronary artery bypass grafting (CABG)-related MI (type 5), which are of uncertain prognostic importance. In addition, for both the MI types, cTn is recommended as the biomarker of choice, the prognostic significance of which is less well validated than CK-MB. Widespread adoption of a MI definition not clearly linked to subsequent adverse events such as mortality or heart failure may have serious consequences for the appropriate assessment of devices and therapies, may affect clinical care pathways, and may result in misinterpretation of physician competence. Rather than using an MI definition sensitive for small degrees of myonecrosis (the occurrence of which, based on contemporary large-scale studies, are unlikely to have important clinical consequences), it is instead recommended that a threshold level of biomarker elevation which has been strongly linked to subsequent adverse events in clinical studies be used to define a "clinically relevant MI." The present document introduces a new definition for "clinically relevant MI" after coronary revascularization (PCI or CABG), which is applicable for use in clinical trials, patient care, and quality outcomes assessment.

Original languageEnglish (US)
Pages (from-to)1563-1570
Number of pages8
JournalJournal of the American College of Cardiology
Volume62
Issue number17
DOIs
StatePublished - Oct 22 2013

Fingerprint

Consensus
Angiography
Myocardial Infarction
Biomarkers
Percutaneous Coronary Intervention
Coronary Artery Bypass
Critical Pathways
Mental Competency
Patient Care
Heart Failure
Outcome Assessment (Health Care)
Clinical Trials
Physicians
Equipment and Supplies
Mortality

Keywords

  • cardiac biomarkers
  • coronary revascularization
  • myocardial infarction definition

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Consideration of a new definition of clinically relevant myocardial infarction after coronary revascularization : An expert consensus document from the society for cardiovascular angiography and interventions (SCAI). / Moussa, Issam D.; Klein, Lloyd W.; Shah, Binita; Mehran, Roxana; Mack, Michael J.; Brilakis, Emmanouil S.; Reilly, John P.; Zoghbi, Gilbert; Holper, Elizabeth; Stone, Gregg W.

In: Journal of the American College of Cardiology, Vol. 62, No. 17, 22.10.2013, p. 1563-1570.

Research output: Contribution to journalArticle

Moussa, Issam D. ; Klein, Lloyd W. ; Shah, Binita ; Mehran, Roxana ; Mack, Michael J. ; Brilakis, Emmanouil S. ; Reilly, John P. ; Zoghbi, Gilbert ; Holper, Elizabeth ; Stone, Gregg W. / Consideration of a new definition of clinically relevant myocardial infarction after coronary revascularization : An expert consensus document from the society for cardiovascular angiography and interventions (SCAI). In: Journal of the American College of Cardiology. 2013 ; Vol. 62, No. 17. pp. 1563-1570.
@article{747fd3403e78414bbfdf305c678784d0,
title = "Consideration of a new definition of clinically relevant myocardial infarction after coronary revascularization: An expert consensus document from the society for cardiovascular angiography and interventions (SCAI)",
abstract = "Numerous definitions have been proposed for the diagnosis of myocardial infarction (MI) after coronary revascularization. The universal definition for MI designates post procedural biomarker thresholds for defining percutaneous coronary intervention (PCI)-related MI (type 4a) and coronary artery bypass grafting (CABG)-related MI (type 5), which are of uncertain prognostic importance. In addition, for both the MI types, cTn is recommended as the biomarker of choice, the prognostic significance of which is less well validated than CK-MB. Widespread adoption of a MI definition not clearly linked to subsequent adverse events such as mortality or heart failure may have serious consequences for the appropriate assessment of devices and therapies, may affect clinical care pathways, and may result in misinterpretation of physician competence. Rather than using an MI definition sensitive for small degrees of myonecrosis (the occurrence of which, based on contemporary large-scale studies, are unlikely to have important clinical consequences), it is instead recommended that a threshold level of biomarker elevation which has been strongly linked to subsequent adverse events in clinical studies be used to define a {"}clinically relevant MI.{"} The present document introduces a new definition for {"}clinically relevant MI{"} after coronary revascularization (PCI or CABG), which is applicable for use in clinical trials, patient care, and quality outcomes assessment.",
keywords = "cardiac biomarkers, coronary revascularization, myocardial infarction definition",
author = "Moussa, {Issam D.} and Klein, {Lloyd W.} and Binita Shah and Roxana Mehran and Mack, {Michael J.} and Brilakis, {Emmanouil S.} and Reilly, {John P.} and Gilbert Zoghbi and Elizabeth Holper and Stone, {Gregg W.}",
year = "2013",
month = "10",
day = "22",
doi = "10.1016/j.jacc.2013.08.720",
language = "English (US)",
volume = "62",
pages = "1563--1570",
journal = "Journal of the American College of Cardiology",
issn = "0735-1097",
publisher = "Elsevier USA",
number = "17",

}

TY - JOUR

T1 - Consideration of a new definition of clinically relevant myocardial infarction after coronary revascularization

T2 - An expert consensus document from the society for cardiovascular angiography and interventions (SCAI)

AU - Moussa, Issam D.

AU - Klein, Lloyd W.

AU - Shah, Binita

AU - Mehran, Roxana

AU - Mack, Michael J.

AU - Brilakis, Emmanouil S.

AU - Reilly, John P.

AU - Zoghbi, Gilbert

AU - Holper, Elizabeth

AU - Stone, Gregg W.

PY - 2013/10/22

Y1 - 2013/10/22

N2 - Numerous definitions have been proposed for the diagnosis of myocardial infarction (MI) after coronary revascularization. The universal definition for MI designates post procedural biomarker thresholds for defining percutaneous coronary intervention (PCI)-related MI (type 4a) and coronary artery bypass grafting (CABG)-related MI (type 5), which are of uncertain prognostic importance. In addition, for both the MI types, cTn is recommended as the biomarker of choice, the prognostic significance of which is less well validated than CK-MB. Widespread adoption of a MI definition not clearly linked to subsequent adverse events such as mortality or heart failure may have serious consequences for the appropriate assessment of devices and therapies, may affect clinical care pathways, and may result in misinterpretation of physician competence. Rather than using an MI definition sensitive for small degrees of myonecrosis (the occurrence of which, based on contemporary large-scale studies, are unlikely to have important clinical consequences), it is instead recommended that a threshold level of biomarker elevation which has been strongly linked to subsequent adverse events in clinical studies be used to define a "clinically relevant MI." The present document introduces a new definition for "clinically relevant MI" after coronary revascularization (PCI or CABG), which is applicable for use in clinical trials, patient care, and quality outcomes assessment.

AB - Numerous definitions have been proposed for the diagnosis of myocardial infarction (MI) after coronary revascularization. The universal definition for MI designates post procedural biomarker thresholds for defining percutaneous coronary intervention (PCI)-related MI (type 4a) and coronary artery bypass grafting (CABG)-related MI (type 5), which are of uncertain prognostic importance. In addition, for both the MI types, cTn is recommended as the biomarker of choice, the prognostic significance of which is less well validated than CK-MB. Widespread adoption of a MI definition not clearly linked to subsequent adverse events such as mortality or heart failure may have serious consequences for the appropriate assessment of devices and therapies, may affect clinical care pathways, and may result in misinterpretation of physician competence. Rather than using an MI definition sensitive for small degrees of myonecrosis (the occurrence of which, based on contemporary large-scale studies, are unlikely to have important clinical consequences), it is instead recommended that a threshold level of biomarker elevation which has been strongly linked to subsequent adverse events in clinical studies be used to define a "clinically relevant MI." The present document introduces a new definition for "clinically relevant MI" after coronary revascularization (PCI or CABG), which is applicable for use in clinical trials, patient care, and quality outcomes assessment.

KW - cardiac biomarkers

KW - coronary revascularization

KW - myocardial infarction definition

UR - http://www.scopus.com/inward/record.url?scp=84886003933&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84886003933&partnerID=8YFLogxK

U2 - 10.1016/j.jacc.2013.08.720

DO - 10.1016/j.jacc.2013.08.720

M3 - Article

VL - 62

SP - 1563

EP - 1570

JO - Journal of the American College of Cardiology

JF - Journal of the American College of Cardiology

SN - 0735-1097

IS - 17

ER -